Marta V. Pinto-Valente

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccination.

Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccination.

Journal: Emerging microbes & infections

Published: August 13, 2025

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries.

Journal: Frontiers in immunology

Published: January 28, 2022

Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom.

Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom.

Journal: EBioMedicine

Published: October 08, 2020

Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing.

Journal: Vaccine

Published: February 05, 2020

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

Journal: Open forum infectious diseases

Published: December 26, 2019

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.

Journal: The Lancet. Infectious diseases

Published: August 07, 2019

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.

Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.

Journal: The Lancet. Infectious diseases

Published: September 25, 2017

Whither vaccines?

Whither vaccines?

Journal: The Journal of infection

Published: June 26, 2017

Pertussis disease and transmission and host responses: insights from the baboon model of pertussis.

Pertussis disease and transmission and host responses: insights from the baboon model of pertussis.

Journal: The Journal of infection

Published: June 26, 2017

Showing 1-9 of 9

Last Updated: 09/26/2026